Aurobindo Pharma’s Subsidiary Receives ‘Official Action Indicated’ Classification from US FDA
Aurobindo Pharma Limited announced on March 17, 2026, that the United States Food and Drug Administration (US FDA) has classified Unit-II of Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma, as ‘Official Action Indicated’ (OAI).Eugia Pharma Specialities Limited’s Unit-II, located in the RIICO Industrial Area, Phase -III, Bhiwadi, Rajasthan, was inspected by the US FDA from November 3 to November 14, 2025. Following the inspection, a ‘Form 483’ was issued, detailing nine observations.
Aurobindo Pharma stated that it currently does not anticipate any impact on business operations as a result of this classification. The company affirmed its commitment to upholding high-quality manufacturing standards across its global facilities.
The company will provide updates to the stock exchanges if further information becomes available.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.